Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $995.00

Key Points

• Guggenheim raised its price target on Regeneron to $995 (from $975) and maintained a "buy" rating, implying roughly a 41.25% upside; the MarketBeat consensus target is about $826.59 (Moderate Buy).
• Q1 beat and capital returns: Regeneron reported EPS of $9.47 vs. $8.91 expected and revenue of $3.61B (up ~19% YoY), and announced a $3 billion share repurchase along with a $0.94 quarterly dividend.
• Despite the beat, the stock traded lower (around $704) as analysts were mixed—some cut targets citing a U.S. Eylea HD shortfall—and insiders have trimmed holdings while institutional ownership remains high (~83%).

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective lifted by investment analysts at Guggenheim from $975.00 to $995.00 in a report released on Friday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. Guggenheim's price objective points to a potential upside of 41.25% from the stock's previous close.

A number of other equities research analysts have also weighed in on the company. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating on the stock in a report on Thursday. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a "buy" rating in a research note on Thursday, April 23rd. Barclays decreased their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating on the stock in a research note on Thursday. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an "equal weight" rating on the stock in a research note on Thursday. Finally, Evercore boosted their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $826.59.

Regeneron Pharmaceuticals Stock Performance

REGN traded down $2.63 during trading on Friday, reaching $704.44. The company's stock had a trading volume of 165,261 shares, compared to its average volume of 743,545. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The company's fifty day moving average price is $756.81 and its 200-day moving average price is $735.17. The company has a market capitalization of $74.47 billion, a price-to-earnings ratio of 17.18, a price-to-earnings-growth ratio of 1.58 and a beta of 0.40. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.39 and a current ratio of 4.15.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts' consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the previous year, the company earned $8.22 EPS. The firm's revenue for the quarter was up 19.0% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 35.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the business's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares of the company's stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,774 shares of company stock worth $2,942,738 in the last ninety days. Insiders own 7.02% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Regeneron Pharmaceuticals by 153.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company's stock valued at $67,969,000 after acquiring an additional 73,176 shares in the last quarter. PGGM Investments boosted its holdings in shares of Regeneron Pharmaceuticals by 9.7% in the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company's stock valued at $52,057,000 after acquiring an additional 8,187 shares in the last quarter. Sound Shore Management Inc CT bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $64,677,000. Rakuten Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $33,121,000. Finally, Ellerson Group Inc. ADV boosted its holdings in shares of Regeneron Pharmaceuticals by 49.2% in the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company's stock valued at $4,556,000 after acquiring an additional 2,671 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 beat and buyback — REGN topped Q1 estimates (revenue ~$3.61B, EPS beat) and announced a $3 billion share repurchase, which supports EPS and signals capital-return confidence. Analysts Cut Forecasts After Q1 (Benzinga)
• Positive Sentiment: Strong product growth drivers — management cited continued strength in Dupixent and growth in Eylea HD in some markets, underpinning near-term revenue momentum. Zacks: Q1 Earnings Top
• Positive Sentiment: Pipeline & milestones — progress in the C5 program (pivotal PNH enrollment, positive phase III for cemdisiran) could drive multi‑indication upside and future approvals. C5 Milestones (Yahoo)
• Positive Sentiment: Dividend — REGN declared a quarterly dividend ($0.94 per share), adding a modest yield and steady cash-return signal to shareholders.
• Neutral Sentiment: Analyst price-target moves — several shops trimmed targets (RBC, Wells Fargo, Truist) but ratings largely remain in the buy/overweight/equal‑weight range, leaving mixed guidance on upside. Benzinga: Analyst Price-Target Changes
• Neutral Sentiment: Long-term valuation view — some outlets (Zacks) still flag REGN as a top value/growth pick for long-term investors, suggesting the pullback may be a buying opportunity for patient holders. Zacks: Long-Term Value Thesis
• Neutral Sentiment: Mixed quarter financials — revenue rose ~19% YoY but net income fell ~10% to $727M, highlighting margin and expense dynamics investors should watch. Pharma‑Tech: Q1 Net Income
• Negative Sentiment: U.S. Eylea HD shortfall — U.S. sales of high‑dose Eylea missed expectations, raising concerns about near‑term ophthalmology revenue and increased competition. Yahoo: Eylea Shortfall
• Negative Sentiment: Market reaction & analyst cuts — despite the beat, the stock fell on investor concerns and several analysts trimmed forecasts and targets, creating downward pressure. Seeking Alpha: Stock Drops Despite Q1 Beat

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.